Navelbine (Vinorelbine Tartrate)

Vinorelbine tartrate, the active ingredient in Navelbine, is a Vinca alkaloid presented as an injectable solution for intravenous use. It is employed in the treatment of certain solid tumours, notably non‑small cell lung cancer and metastatic breast cancer.

GNH USA supplies Navelbine as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Vinorelbine is a Vinca alkaloid used in the management of solid tumours that rely on rapid cell division. - Non‑small cell lung cancer: improves disease control when used in combination chemotherapy regimens. - Metastatic breast cancer: provides benefit after prior anthracycline or taxane therapy. - Advanced solid tumours: may be considered in selected cases where other options are limited.

Vinorelbine may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Vomiting: occasional episodes, often controllable with anti‑emetics. - Neutropenia: reduced white blood cell count, increasing infection risk. - Anemia: lowered red blood cell levels causing fatigue. - Fatigue: general tiredness during treatment. - Alopecia: hair thinning or loss.

Serious or Rare Side Effects: - Severe neutropenia with febrile infection: requires immediate medical attention. - Pulmonary toxicity: breathlessness or cough indicating lung injury. - Hypersensitivity reactions: rash, itching, or anaphylaxis. - Cardiac arrhythmia: irregular heartbeats observed in some patients. - Severe hypotension: sudden drop in blood pressure during infusion.

Before initiating therapy, clinicians should assess patient suitability and monitor for potential complications. - Blood count monitoring: perform regular CBC to detect neutropenia or anemia. - Liver function assessment: evaluate hepatic enzymes as vinorelbine is metabolised hepatically. - Cardiac evaluation: baseline ECG recommended for patients with cardiac history. - Infection risk: avoid use in patients with active severe infections. - Renal impairment caution: adjust monitoring in patients with reduced kidney function. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Vinorelbine can interact with other medicines, altering its safety or effectiveness.

Major Interactions (Avoid): - Concurrent myelosuppressive chemotherapy: may exacerbate bone‑marrow suppression. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase vinorelbine plasma levels. - High‑dose corticosteroids: may potentiate neutropenia.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce drug exposure. - Anticoagulants (e.g., warfarin): monitor coagulation parameters. - Antiemetic agents (e.g., ondansetron): assess for additive QT prolongation risk.